{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:36Z","timestamp":1790710176176,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the sociodemographic, medical and management characteristics of patients using intravitreal (IVT) anti\u2010vascular endothelial growth factors (VEGF) in France.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational study was conducted in patients treated with IVT ranibizumab or aflibercept, aged 18\u2009years or older using the French National Health Insurance Databases covering 99% of the French population. Patients currently treated in 2018 were included in a cross\u2010sectional approach to describe treatment history over the previous 6\u2009years. Patients newly treated between 2014 and 2018 were included in a longitudinal approach to describe treatment management during up to 6\u2009years of follow\u2010up. Sociodemographic characteristics and medical history were described in both populations. The analyses were performed at the patient level, as no distinction between the eyes could be made.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 224\u2009775 current users of IVT anti\u2010VEGF in 2018 (mean age 78.1\u2009\u00b1\u200911.3\u2009years, 60% female) and 330\u2009969 new users between 2014 and 2018 (mean age 75.9\u2009\u00b1\u200912.0\u2009years, 59% female) were included. In both populations cardiovascular comorbidities or risk factors were frequent and the main treatment indications were age\u2010related macular degeneration and diabetic macular oedema. Among current users of IVT anti\u2010VEGF in 2018, the mean number of years receiving a treatment was 2.9\u2009\u00b1\u20092.0\u2009years, with a mean of 13.7\u2009\u00b1\u200911.8 dispensations. In the longitudinal approach, a 26% increase in IVT anti\u2010VEGF initiation was observed between 2014 and 2018. For new users, the mean number of years receiving a treatment was 1.6\u2009\u00b1\u20091.6 and 67% had at least three dispensations within the first three months. A treatment interruption was observed for 83% of new users and occurred on average of 6.1\u2009\u00b1\u20098.1\u2009months after initiation. The mean number of dispensations was 4.8\u2009\u00b1\u20092.8 in the first year and 2.2\u2009\u00b1\u20092.9 in the second year. The mean number of eye monitoring examinations was 6.5\u2009\u00b1\u20094.7 in the first year and 4.6\u2009\u00b1\u20094.4 in the second year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study described the real\u2010world conditions of IVT anti\u2010VEGF dispensing at the entire French population scale. Less frequent dispensations and surveillance examinations were observed than in monthly schemes applied in registration trials for IVT anti\u2010VEGF. These results may indicate a lack of systematic monitoring associated with fewer injections and\/or clinicians\u2019 preference for more flexible and personalized injection schemes than those originally recommended.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.14929","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T23:56:00Z","timestamp":1623714960000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intravitreal anti\u2010VEGF use in France: a cross\u2010sectional and longitudinal Nationwide observational study"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4097-8495","authenticated-orcid":false,"given":"Sophie","family":"Billioti de Gage","sequence":"first","affiliation":[{"name":"EPI\u2010PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)) Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bertrand","sequence":"additional","affiliation":[{"name":"EPI\u2010PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)) Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Ophthalmologic Center Ch\u00e2tellerault France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI\u2010PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)) Saint\u2010Denis France"},{"name":"University Paris\u2010Saclay UVSQ, University Paris\u2010Sud, Inserm Anti\u2010Infective Evasion and Pharmacoepidemiology, CESP Montigny le Bretonneux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21269"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00027-7"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.04.001"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31827b6324"},{"key":"e_1_2_6_9_1","unstructured":"European Medicine Agency(2009):Lucentis (ranibizumab) \u2010 summary of product characteristics(Last updated 23\/10\/2020). Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lucentis\u2010epar\u2010product\u2010information_en.pdf. (Accessed on 20 Apr 2021)."},{"key":"e_1_2_6_10_1","unstructured":"European Medicine Agency(2012):Eylea (aflibercept) \u2010 summary of product characteristics(Last updated 01\/03\/2021). Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/eylea\u2010epar\u2010product\u2010information_en.pdf. (Accessed on 20 Apr 2021)."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.01.028"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.08.016"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-122340"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801537"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.02.027"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.04.003"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16071"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314422"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.143"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S275977"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181de5609"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.6205"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00736.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-04214-w"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2016.12.003"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12517"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.02.024"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2017-000109"},{"key":"e_1_2_6_32_1","article-title":"Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study","volume":"353","author":"Weill A","year":"2016","journal-title":"BMJ"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13539"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.14929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.14929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T20:28:12Z","timestamp":1692995292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.14929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/aos.14929"],"URL":"https:\/\/doi.org\/10.1111\/aos.14929","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"2020-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}